This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system.
CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients with Acute Intracerebral Hemorrhage (ICH)
Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety Study
Eligibility & Criteria
Inclusion Criteria:- Males and females – Intracerebral Hemorrhage as the cause of stroke symptoms – Onset of symptoms within 6 hours – Full functional independence prior to the present stroke Exclusion Criteria:- Unconsciousness – Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. – Severe illness with life expectancy less than 6 months. – Known severe kidney disorder. – Current known alcohol or illicit drug abuse or dependence. – Pregnant or breast-feeding. – Treatment with acetazolamide and methotrexate is not permitted during the infusion – Participation in a previous clinical study within 7 days. – Meets all other exclusion criteria
This study is not yet recruiting please visit http://www.astrazeneca.com for further details and contact information.